MA56098A - Immunomodulateurs hétérocycliques utilisés comme inhibiteur de point de contrôle pdl1 - Google Patents
Immunomodulateurs hétérocycliques utilisés comme inhibiteur de point de contrôle pdl1Info
- Publication number
- MA56098A MA56098A MA056098A MA56098A MA56098A MA 56098 A MA56098 A MA 56098A MA 056098 A MA056098 A MA 056098A MA 56098 A MA56098 A MA 56098A MA 56098 A MA56098 A MA 56098A
- Authority
- MA
- Morocco
- Prior art keywords
- heterocyclic
- checkpoint inhibitor
- immunomodulators used
- pdl1
- pdl1 checkpoint
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19179072 | 2019-06-07 | ||
| PCT/EP2020/065646 WO2020245372A1 (fr) | 2019-06-07 | 2020-06-05 | Immunomodulateurs hétérocycliques utilisés comme inhibiteur de point de contrôle pdl1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA56098A true MA56098A (fr) | 2022-04-13 |
| MA56098B1 MA56098B1 (fr) | 2023-10-31 |
Family
ID=66793871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56098A MA56098B1 (fr) | 2019-06-07 | 2020-06-05 | Immunomodulateurs hétérocycliques autant qu'inhibiteurs de pdl1 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12624022B2 (fr) |
| EP (1) | EP3980413B1 (fr) |
| JP (1) | JP7768770B2 (fr) |
| KR (1) | KR102939670B1 (fr) |
| CN (1) | CN113966329B (fr) |
| AU (1) | AU2020286962B2 (fr) |
| BR (1) | BR112021023780A2 (fr) |
| CA (1) | CA3138494A1 (fr) |
| ES (1) | ES2956866T3 (fr) |
| HR (1) | HRP20230873T1 (fr) |
| HU (1) | HUE063236T2 (fr) |
| MA (1) | MA56098B1 (fr) |
| MD (1) | MD3980413T2 (fr) |
| MX (1) | MX2021015048A (fr) |
| PL (1) | PL3980413T3 (fr) |
| RS (1) | RS64681B1 (fr) |
| SM (1) | SMT202300280T1 (fr) |
| WO (1) | WO2020245372A1 (fr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4815773B2 (ja) | 2003-09-17 | 2011-11-16 | 住友化学株式会社 | シンナモイル化合物及びその用途 |
| MX2016002544A (es) * | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
| US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| EP3474845B1 (fr) | 2016-06-27 | 2024-03-20 | ChemoCentryx, Inc. | Composés immunomodulateurs |
| CN109689640B (zh) | 2016-07-08 | 2022-01-04 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
| JP7150745B2 (ja) * | 2017-03-27 | 2022-10-11 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤としての置換イソキノリン誘導体 |
-
2020
- 2020-06-05 PL PL20730279.5T patent/PL3980413T3/pl unknown
- 2020-06-05 CA CA3138494A patent/CA3138494A1/fr active Pending
- 2020-06-05 AU AU2020286962A patent/AU2020286962B2/en active Active
- 2020-06-05 MD MDE20220403T patent/MD3980413T2/ro not_active IP Right Cessation
- 2020-06-05 RS RS20230805A patent/RS64681B1/sr unknown
- 2020-06-05 HR HRP20230873TT patent/HRP20230873T1/hr unknown
- 2020-06-05 SM SM20230280T patent/SMT202300280T1/it unknown
- 2020-06-05 MX MX2021015048A patent/MX2021015048A/es unknown
- 2020-06-05 KR KR1020217042602A patent/KR102939670B1/ko active Active
- 2020-06-05 HU HUE20730279A patent/HUE063236T2/hu unknown
- 2020-06-05 US US17/595,711 patent/US12624022B2/en active Active
- 2020-06-05 CN CN202080041699.XA patent/CN113966329B/zh active Active
- 2020-06-05 EP EP20730279.5A patent/EP3980413B1/fr active Active
- 2020-06-05 ES ES20730279T patent/ES2956866T3/es active Active
- 2020-06-05 WO PCT/EP2020/065646 patent/WO2020245372A1/fr not_active Ceased
- 2020-06-05 MA MA56098A patent/MA56098B1/fr unknown
- 2020-06-05 JP JP2021572339A patent/JP7768770B2/ja active Active
- 2020-06-05 BR BR112021023780A patent/BR112021023780A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020286962B2 (en) | 2025-10-16 |
| HRP20230873T1 (hr) | 2024-02-16 |
| EP3980413A1 (fr) | 2022-04-13 |
| EP3980413B1 (fr) | 2023-07-19 |
| JP7768770B2 (ja) | 2025-11-12 |
| US20220259186A1 (en) | 2022-08-18 |
| US12624022B2 (en) | 2026-05-12 |
| EP3980413C0 (fr) | 2023-07-19 |
| RS64681B1 (sr) | 2023-11-30 |
| ES2956866T3 (es) | 2023-12-29 |
| MD3980413T2 (ro) | 2023-12-31 |
| PL3980413T3 (pl) | 2023-12-27 |
| WO2020245372A1 (fr) | 2020-12-10 |
| KR102939670B1 (ko) | 2026-03-13 |
| CN113966329B (zh) | 2024-08-13 |
| CN113966329A (zh) | 2022-01-21 |
| SMT202300280T1 (it) | 2023-11-13 |
| CA3138494A1 (fr) | 2020-12-10 |
| HUE063236T2 (hu) | 2024-01-28 |
| MX2021015048A (es) | 2022-01-18 |
| MA56098B1 (fr) | 2023-10-31 |
| BR112021023780A2 (pt) | 2022-01-11 |
| JP2022535879A (ja) | 2022-08-10 |
| KR20220017942A (ko) | 2022-02-14 |
| AU2020286962A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4069212A4 (fr) | Inhibiteurs de hif-2 alpha | |
| EP4007752C0 (fr) | Inhibiteurs de kif18a | |
| EP3898616C0 (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| DK3873903T3 (da) | Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere | |
| DK4219492T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| DK4212529T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| EP3843714C0 (fr) | Inhibiteurs de cd73 | |
| EP4076418A4 (fr) | Inhibiteurs de sos1 | |
| DK3684767T3 (da) | Heterocykliske forbindelser som pad-inhibitorer | |
| DE102020112518B8 (de) | Toner | |
| JP1679815S (ja) | エアロゾル発生器用充電器 | |
| IL284591A (en) | Fxr (nr1h4) modulating compounds | |
| MA55633A (fr) | Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| MA46045A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| DK4051688T3 (da) | Cd73-hæmmere | |
| MA44860A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| EP3966213A4 (fr) | Inhibiteurs de cdk | |
| EP3946936A4 (fr) | Couvercle recyclable haute performance | |
| DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
| EP3801500A4 (fr) | Inhibiteurs de sarm1 | |
| EP3787635A4 (fr) | Inhibiteurs de cd73 | |
| MA46203A (fr) | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase | |
| EP3980011A4 (fr) | Inhibiteurs de sarm1 | |
| EP3681499A4 (fr) | Composés utilisés comme inhibiteurs de ras et leur utilisation |